急性心肌梗塞急性期治疗的重点在于挽救濒危的心肌、治疗心衰 ,以改善生命预后。虽然目前日本能够实施导管介入进行心肌救护治疗的医疗设施很多 ,但并不是全部患者在急性期都能接受这项治疗 ,而且 ,介入后产生的罕见无再灌流 (noreflow)现象等问题尚未完全解决。其中 ,通过药物 Acute myocardial infarction in the acute phase of treatment is focused on saving endangered myocardium, the treatment of heart failure, to improve the prognosis of life. Although there are many medical facilities in Japan where catheterization can be used for myocardial infarction, not all patients will receive this treatment during the acute phase, and the rare non-noreflow phenomenon after intervention has not been completely resolved . Among them, through the drug